Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 3—March 2011

Research

Mycobacterium tuberculosis Cluster with Developing Drug Resistance, New York, New York, USA, 2003–2009

Bianca R. PerriComments to Author , Douglas Proops, Patrick K. Moonan, Sonal S. Munsiff, Barry N. Kreiswirth, Natalia Kurepina, Christopher Goranson, and Shama D. Ahuja
Author affiliations: Author affiliations: New York City Department of Health and Mental Hygiene, New York, New York, USA (B.R. Perri, D. Proops, S.S. Munsiff, C. Goranson, S.D. Ahuja); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (B.R. Perri, P.K. Moonan, S.S. Munsiff); Public Health Research Institute Tuberculosis Center, Newark, New Jersey, USA (B.N. Kreiswirth, N. Kurepina)

Main Article

Table

Characteristics of 54 TB patients, by drug susceptibility test results, New York, New York, USA, 2003–2009*

Characteristic All patients Type of Mycobacterium tuberculosis
p value
Drug-susceptible, n = 37 Isoniazid-resistant, n = 17
Median age at TB diagnosis, y (range) 41 (10–77) 42 (12–77) 39 (10–52) 0.12
Male sex
37 (69)
27 (73)
10 (59)
0.30
Race/ethnicity
Asian 1 (2) 1 (3) 0 1.00†
Hispanic 13 (24) 8 (22) 5 (29) 0.73†
Black, non-Hispanic
40 (74)
28 (76)
12 (71)
0.74†
Country of origin
United States 36 (67) 22 (59) 14 (82) 0.10
Foreign 17 (31) 14 (38) 3 (18) 0.14
Unknown
1 (2)
1 (3)
0
1.00†
History of illegal drug use‡ 22 (41) 12 (32) 10 (59) 0.07
History of homelessness 13 (24) 8 (22) 5 (29) 0.73†
History of incarceration
12 (22)
4 (11)
8 (47)
<0.01†
Pulmonary site of TB§ 48 (89) 32 (87) 16 (94) 0.65†
Cavitary (among cases with pulmonary site of disease) 12 (25) 7 (22) 5 (31) 0.50†
Acid-fast bacilli smear positive for respiratory specimen
38 (70)
24 (65)
14 (82)
0.19
HIV status
Positive 14 (26) 9 (24) 5 (29) 0.74†
Negative 37 (69) 26 (70) 11 (65) 0.68
Unknown 3 (6) 2 (5) 1 (6) 1.00†

*Values are no. (%) unless otherwise indicated. TB, tuberculosis.
†By Fisher exact test.
‡Use of injection (e.g., heroin) or noninjection (e.g., marijuana or cocaine) drugs indicated on any patient record.
§Includes patients with only pulmonary sites of disease and patients with pulmonary and extrapulmonary sites of disease.

Main Article

TOP